en English

Dominant Players In Point of Care Molecular Diagnostics

The global point-of-care molecular diagnostics market size is projected to reach USD 4.1 billion by 2026 from USD 2.8 billion in 2021, at a CAGR of 8.2%

A new report titled, “Global Point of Care Molecular Diagnostics Market”, has been added by MarketsandMarkets™ INC to its vast database of research reports. The Global Point of Care Molecular Diagnostics Market is poised to grow at a CAGR of 8.2% during the forecast period, 2021-2026. This intelligent study provides the definition, description, and the overall forecasts of the global market, considering the market segments and sub-segments, which includes the product types, technologies, end-users, industry verticals, and the key geographies.

The report examines the global market with respect to the industry trends, growth rate, prospects, drivers, restraints, threats, and lucrative opportunities, by means of distinguishing the high-growth segments of the market through the various stakeholders. The statistical surveying study also elucidates the different strategies, collaborations, merger and acquisitions, product launches, innovations, and the activities in the R&D sector in the Global Point of Care Molecular Diagnostics Market.

Request a Sample copy of Point of Care Molecular Diagnostics Study: https://www.marketsandmarkets.com/requestsampleNew.asp?id=143524127

The report presents a lucid picture of the current industry landscape, including the historical and projected market size, based on value, technological innovations, micro- and macroeconomic components, and governing factors in the market. The global Point of Care Molecular Diagnostics market research report ends with the brief summary of the leading players operating in the market, their product offerings, key developments, SWOT analysis, invest feasibility and returns, and the growth trends and forecasts.

Some key players in the point-of-care molecular diagnostics market (2021- 2026):

  • Abbott Laboratories (US)
  • Hoffmann-La Roche Ltd. (Switzerland)
  • bioMérieux SA (France)
  • Danaher Corporation (US)
  • Quidel Corporation (US)
  • QIAGEN N.V. (Netherlands)
  • Co-Diagnostics, Inc. (US)
  • Biocartis NV (Belgium)
  • Meridian Bioscience, Inc. (US)
  • Thermo Fisher Scientific, Inc. (US)
  • Lucira Health, Inc. (US)
  • Cue Health (US)
  • OpGen, Inc. (US)
  • Binx Health, Inc. (US)
  • Molbio Diagnostics Pct. Ltd. (India)
  • Genomadix (Canada)
  • Visby Medical, Inc. (US)
  • QuikPath PTE Ltd. (Singapore)
  • MD-Bio (US)
  • QuantuMDx Group Ltd. (UK)
  • Aidian Oy (Finland)
  • GeneSTAT Molecular Diagnostics, LLC (US) and Among Others

COVID-19 Impact on Global Point-of-Care Molecular Diagnostics Industry:

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has moved from a regional crisis to a global pandemic in just a matter of a few weeks. The COVID-19 pandemic negatively affected the overall sales of most of the companies but had a positive impact on the point-of-care molecular diagnostics market because of the use of molecular diagnostic methods for COVID-19 testing. Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of reagents. However, a resurgence in testing numbers is seen as countries gradually ease restrictions on movement. With the COVID-19 pandemic, responding to infectious disease has become a pressing medical issue worldwide. In addition to the development of vaccines and therapeutic drugs, there is a growing call for the development of more precise and simple testing technologies and the expansion of testing structures. COVID-19 has also impacted the regulatory environment and practices, as governments and healthcare providers face unprecedented challenges. Regulatory authorities utilized methods to speed approval of diagnostic products. Companies have taken strategic developments to introduce COVID-19 rapid tests, sustain their revenues, and nullify the impact of COVID-19 on their operational capabilities

This report categorizes the point-of-care molecular diagnostics market into the following segments and subsegments:

By Product & Service

  • Assays & kits
  • Instruments & Analyzers
  • Software & Services

By Technology

  • RT-PCR
  • Other technologies

By Application

  • Respiratory Diseases
  • Sexually Transmitted Diseases
  • Hospital-acquired Infections
  • Cancer
  • Hepatitis
  • Gastrointestinal Disorders
  • Other Applications

By End User

  • Physicians’ Offices
  • Hospitals & ICUs
  • Research Institutes
  • Other End Users

Download a PDF Copy: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=143524127

Some of the key geographies mentioned in this report include:

  • North America (U.S and Canada and rest of North America)
  • Europe (Germany, France, Italy and Rest of Europe)
  • Asia-Pacific (China, Japan, India, South Korea and Rest of Asia-Pacific)
  • LAMEA (Brazil, Turkey, Saudi Arabia, South Africa and Rest of LAMEA)